Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02494778 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
A Phase 2 study, sponsored by Prilenia.
- Terminated
- Registry status
- Phase 2
- Development phase
- 248
- Enrollment target
NCT02494778: Clinical Trial Phase 2 study, sponsored by Prilenia.
NCT02494778 is a Phase 2 study that was terminated before completion, run by Prilenia. The registered enrollment target is 248 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02494778, a Phase 2 study, was terminated before completion, sponsored by Prilenia.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 248 participants
- Enrollment target
Study Summary
The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).
Primary Outcome
From signature of the informed consent form through the end of the study, which was defined as Week 106
Interventions
- DRUG Pridopidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2015-09-24 |
| Est. Completion | 2018-01-12 |
| Phase | Phase 2 |
Why NCT02494778 stopped before completion
NCT02494778 is an interventional study that assigns participants to a tested intervention. The registered 248 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% higher).
The record links to 0 conditions, and to 1 intervention - of which Pridopidine is the first listed.
NCT02494778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02494778 about?
NCT02494778 is a clinical study titled "A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease". The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).
What is the current status of trial NCT02494778?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 248 participants. The study started on 2015-09-24. Estimated completion is 2018-01-12.
What interventions are being tested in trial NCT02494778?
The interventions under investigation include: Pridopidine (DRUG).
Who is sponsoring clinical trial NCT02494778?
This trial is sponsored by Prilenia, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02494778's enrollment target sits among peer trials
248 234th of 2000 higher than 1,767 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577911 · 248 participants
How is Social Connection Represented in the Brain?
- NCT04777994 · 248 participants · Phase 1
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- NCT04792489 · 248 participants · Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
- NCT04830137 · 248 participants · Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI